Literature DB >> 16883259

[Hormonal regulation of lipoprotein metabolism: the role in pathogenesis of coronary heart disease].

E I Sokolov, V A Metel'skaia, N V Perova, G N Shchukina.   

Abstract

The character and role of hormonal dysregulation of lipoprotein metabolism during postprandial hyperlipemia were studied in patients with coronary heart disease (CHD) and hyperthyroidism as compared with healthy subjects. Pronounced hypertriglyceridemia alongside with the decreased high density lipoprotein cholesterol (HDL C) after standard fat load were associated with increased level of insulin and decreased level of cortisol. Moreover, in CHD patients fasting hyperinsulinemia becoming even stronger postprandially resulted in prevalence of antilipolytic action of insulin over lipid-mobilizing effect of cortisol; and an extended postprandial hypertriglyceridemia took place. Patients with hyperthyroidism and low cholesterol level both in atherogenic LDL and antiatherogenic HDL, demonstrated decreased level of apo AI (as in CHD patients) and apo B (three times lower than in CHD patients). Very low ratio of apo B/AI in patients with hyperthyroidism both in fasting and postprandial state was a clear indication of their lipoprotein profile antiatherogeneity. Thus, in patients with hyperthyroidism despite of low HDL C and apo AI levels, antiatherogenic properties of lipoprotein profile are probably determined by very low apo B/AI ratio induced by thyroid hormones, and might be explained by the influence of thyroid hormones on the expression of genes coding these apoproteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883259

Source DB:  PubMed          Journal:  Kardiologiia        ISSN: 0022-9040            Impact factor:   0.395


  1 in total

1.  Prevalence of metabolic syndrome and obesity in adolescents aged 12 to 19 years: comparison between the United States and Korea.

Authors:  Jinkyung Park; David C Hilmers; Jason A Mendoza; Janice E Stuff; Yan Liu; Theresa A Nicklas
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.